Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

8.280 +0.110 (+1.35%)
Streaming Delayed Price Updated: 10:44 AM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent Biosolutions

< Previous 1 2 3 4 5 6 7 8 9 Next >
Nasal-Spray Millionaire: Indivior's Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment
The FDA has approved Indivior PLC's (OTC: INVVY) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. 
Via Benzinga
Why Emergent BioSolutions Stock Inched Slightly Higher Today
Investors approved, if not enthusiastically, their company's latest asset sale. 
Via The Motley Fool
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
From Emergent BioSolutions
Via GlobeNewswire
Recap: Emergent BioSolutions Q1 Earnings
 
Via Benzinga
Why Emergent BioSolutions Stock Is Soaring Today
Emergent received a key approval from the FDA, but just how good is this news? 
Via The Motley Fool
FDA Approves First OTC Naloxone Nasal Spray For Opioid Overdose
 
Via Benzinga
Why Emergent BioSolutions Stock Is Sinking Today
Investors reacted negatively to an analyst's downgrade of the healthcare stock. 
Via The Motley Fool
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,... 
Via Benzinga
Emergent BioSolutions (EBS) Q1 2023 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Emergent BioSolutions Reports Financial Results For First Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent Plans $50 Price Point For Narcan OTC Version For Opioid Overdose Reversal
Emergent BioSolutions Inc (NYSE: EBS) looks to price its over-the-counter (OTC) version of its opioid overdose reversal Narcan at around $50 per carton of two 4 mg doses. 
Via Benzinga
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
From Emergent BioSolutions
Via GlobeNewswire
CPI Sent Market Surging - But Some Stocks Took A Hit: Spotlight On Top Gainers And Hard-Hit Decliners
The market is trading higher on Wednesday after the Labor Department reported the latest Consumer Price Index figure for the month of March. While most stocks are trading higher alongside the major... 
Via Benzinga
Tesla, Apple, Riot Platforms, AMC, Emergent Biosolutions: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. 
Via Benzinga
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
 
Via Benzinga
Micron Technology, Greenbrier Companies And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Nasdaq Composite falling over 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
Sprinklr, EVgo, Emergent BioSolutions And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Emergent Biosciences (EBS) Stock Pops as FDA Approves Over-the-Counter Narcan
EBS stock is on the move as Emergent Biosciences expects its opioid emergency drug to be available soon without a prescription. 
Via InvestorPlace
FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan
Narcan, the prescription nasal spray that reverses opioid overdoses can now be sold over the counter (OTC), said the FDA on Wednesday, reported the NY Times, thereby authorizing a move that has... 
Via Benzinga
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
From Emergent BioSolutions
Via GlobeNewswire
Why Emergent Biosolutions Stock Is Surging Today
Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Wednesday following reports the U.S. Food and Drug Administration approved the company's Naloxone nasal spray for over-the-counter use. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares rose 36.7% to $0.1914 in pre-market trading after the company reported strong revenue and margin growth for the year ended 2022. 
Via Benzinga
Cal-Maine Foods, Lululemon Athletica And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.